Plasma and tissue protein binding of drugs in pharmacokinetics

Drug Metabolism Reviews

Volumn 5, Issue 1, 1976, Pages 43-140

  Jusko, William J ^a   Gretch, Mark ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMINOID; ANTIBODY; DRUG; PLASMA PROTEIN; CHLORCYCLIZINE; CHLORPROMAZINE; CLOXACILLIN; COLISTIN; CYCLIZINE; DEMECLOCYCLINE; DICOUMAROL; DIGOXIN; ERYTHROMYCIN; GENTAMICIN; IMIPRAMINE; KANAMYCIN; METICILLIN; NEOMYCIN; OXYTETRACYCLINE; PENICILLIN G; PHENYLBUTAZONE; PHENYTOIN; POLYMYXIN; PROPRANOLOL; SALICYLIC ACID; STREPTOMYCIN; SULFADIMETHOXINE; TETRACYCLINE; WARFARIN; ACETANILIDE; ADRENERGIC RECEPTOR STIMULATING AGENT; AMPHETAMINE; ANTIDIABETIC AGENT; ANTINEOPLASTIC AGENT; BARBITURIC ACID DERIVATIVE; BILIRUBIN; BROMSULFOPHTHALEIN; BUPIVACAINE; CLOFIBRATE; DAPSONE; DIAZOXIDE; DIGITOXIN; DIURETIC AGENT; DOXYCYCLINE; INDOCYANINE GREEN; LIDOCAINE; METACYCLINE; NAPROXEN; PARACETAMOL; PHENACETIN; RIFAMPICIN; SULFANILAMIDE; SULFAPHENAZOLE;

AGING; ANIMAL; DRUG INTERACTION; GENERAL ASPECTS OF DISEASE; GUINEA PIG; HAPLORHINI; HUMAN; KINETICS; METABOLISM; PROTEIN BINDING; RABBIT; REVIEW; SPECIES DIFFERENCE; STRUCTURE ACTIVITY RELATION; DRUG PROTEIN BINDING; NORCHLOROCYCLIZINE; NORCYCLIZINE; PHARMACOKINETICS;

AGING; ALBUMINS; ANIMAL; ANTIBODIES; BLOOD PROTEINS; DISEASE; DRUG INTERACTIONS; GUINEA PIGS; HAPLORHINI; HUMAN; KINETICS; PHARMACEUTICAL PREPARATIONS; PROTEIN BINDING; RABBITS; SPECIES SPECIFICITY; STRUCTURE-ACTIVITY RELATIONSHIP; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0017099526     PISSN: 03602532     EISSN: None     Source Type: Journal    
DOI: 10.3109/03602537608995839     Document Type: Article

References (431)

1. The Interaction of Drugs and Plasma Proteins
2. The Binding of Drugs by Plasma Proteins
3. The Nature of Drug-Protein Interaction
4. Physical Methods for Studying Drug-Protein Binding
5. Effect of Binding to Plasma Proteins on the Distribution, Activity and Elimination of Drugs
6. Competition between Drugs and Normal Substrates for Plasma and Tissue Binding Sites
7. Protein Binding
8. Binding of Drugs
9. Drug-Protein Interaction
10. Protein Interactions with Small Molecules
11. Drug-Protein Binding.”
12. Lymph and Plasma Proteins: Barriers to Their Movement Throughout the Extracellular Fluid
13. Tissue Distribution of I131 Labeled Human Serum Albumin Following Intravenous Administration
14. Albumin Metabolism
15. Studies of I131 Albumin Catabolism and Distribution in Normal Young Male Adults
16. Studies of the Metabolism and Distribution of Albumin with Autologous I113 Albumin in Healthy Men.
17. Study of the Relationship between Plasma Volume and Transcapillary Protein Exchange Using I131 Labeled Albumin and I125 Labeled Globulin
18. Metabolism of I131 Labeled Human Albumin
19. Serum Albumin Turnover in Normal Subjects and Patients with Cirrhosis Measured by I131 Labeled Human Albumin
20. The Rates of Distribution and Catabolism of Albumin in Normal Subjects and in Patients with Cirrhosis of the Liver
21. Correlation and Regression Analysis
22. The Distribution of Proteins between Intra and Extravascular Spaces in Health and Disease
23. Albumin, Alpha 1, 2, Beta and Gamma Globulin in Cancer and Other Diseases
24. Serum Proteins in Prostatic Cancer I. Relationship Between Clinical Stage and Level
25. Alterations in Plasma Protein Patterns in Disease
26. Albumin Catabolism in Burns and Following Surgical Procedures
27. A Study of Plasma Protein Variation in Surgical Procedure
28. Turnover of Human Serum Albumin Before and After Operation
29. Studies of Burns IX. The Distribution and Losses through the Wound of I131 Albumin Measured by Whole-Body Counting
30. Effect of Hormonal Contraceptives and Pregnancy on Serum Protein Pattern
31. Effect of Neoplastic and Allied Diseases on Concentration of Plasma Proteins
32. I131 Albumin Degradation in Patients with Neoplastic Diseases
33. Albumin Synthesis
34. Hepatitis and Cirrhosis
35. Recent Advances in Clinical Interpretation of Electrophoretic Fractionations of the Serum Proteins
36. Albumin Metabolism in the Nephrotic Syndrome in Adults
37. Protein Loss into the Sputum and Faeces of Patients with Chronic Bronchitis: Lung Clearance of 51Cr Labeled Human Serum Albumin
38. Studies on the Proteins of Human Bronchial Secretion
39. I131 Albumin Turnover and Loss of Proteins into the Sputum in Chronic Bronchitis
40. Albumin Metabolism in Cystic Fibrosis
41. Albumin Metabolism in Diabetes Mellitus
42. Cigarette Smoking and Serum Chemistry Tests
43. Low Urea-Nitrogen and Elevated Serum Albumin in Anxiety, Neuroses, and Psychoses
44. Serum Albumin and Urea During States of Anxiety and Depression”
45. Kinetics of Elimination of Drugs Possessing High Affinity for the Plasma Protein
46. Pharmacokinetic Models Regarding Protein Binding of Drugs
47. Numerical Solution of Nonlinear Pharmacokinetic Equations: Effects of Plasma Protein Binding on Drug Distribution and Elimination
48. Effects of Protein Binding of Drugs on Areas under Plasma Concentration-Time Curver
49. Pharmacokinetic Consequences of Plasma Protein Binding of Drugs
50. Potential Effects of the Plasma Proteins on Drug Distribution
51. Equations for the Prediction of Normal Values for Exchangeable Na+, Exchangeable K+, Extracellular Fluid Volume and Total Body Water
52. A Safer Method for Measuring Body Fluid Compartments in Patients
53. Body Water Compartments and the Distribution of Drugs
54. Body Composition and Electrolyte Studies
55. Thiopental Pharmacokinetics
56. Methotrexate Pharmacokinetics
57. In vitro-in vivo Correlation of Drug Metabolism-Deamination of 1-β-D-Arabinofuranosylcytosine
58. Factors Affecting the Pharmacokinetics of Some Psychoactive Drugs
59. Ligandin: A Hepatic Protein Which Binds Steroids, Bilirubin, Carcinogens, and a Number of Exogenous Organic Anions
60. Immunological Studies of Y Protein
61. The Role of the Y and Z Hepatic Proteins in the Excretion of Radiographic Contrast Materials
62. Modulation of Pharmacokinetics by Modification of the Various Factors Involved
63. Binding of a New Antitumor Agent, Thalicorpine, to DNA
64. Common Receptor-Complement Features Among Some Antileukemic Compounds”
65. The Reversible Binding of Some Aromatic and Cyclic Compounds to Biopolymers in vitro
66. Reaction between DNA and Quinacrine and Other Antimalarials
67. The Ocular Deposition of Chloroquine
68. The Concentration of Phenothiazines in the Eye of Experimental Animals
69. Cocaine-Binding by the Pigmented and the Non-Pigmented Iris and Its Relevance to the Mydriatic Effect
70. Accumulation of (-)−14C- Ephedrine by the Pigmented and the Non-Pigmented Iris
71. The Binding Properties of Melanin: In vivo and in vitro
72. The Tetracyclines: Chlortetracyline, Oxytetracycline, Tetracycline, and Demethylchortetracycline
73. Binding of Digitoxin and Some Related Cardenolides to Human Plasma Proteins
74. The Binding of Digoxin by the Serum Proteins
75. The Uptake of Cardiac Glycosides in Relation to Their Actions in Isolated Cardiac Muscle
76. Effects of Digoxin-Specific Antibodies on Accumulation and Binding of Digoxin by Human Erythrocytes
77. Enzymes as Drug Receptors: Transport ATPase
78. Interaction of Cardiac Glycosides with Serum Albumin and Contractile Proteins
79. The Distribution and Concentration of Tritiated Digoxin in Human Tissues
80. Myocardial Distribution of Digoxin and Renal Function
81. Concentration of Ethambutal in CSF Fluid in Man as a Function of the Non-Protein Bound Drug Fraction in Serum
82. The Distribution of Antibacterial Agents between Plasma and Lymph in the Dog”
83. Binding of Various Penicillins by Plasma and Peripheral Lymph Obtained from Dog
84. A Method for Measurement of Antibiotics in Human Interstitial Fluid”
85. Concentration of Antibacterial Agents in Interstitial Tissue Fluid
86. Penetration of Antibiotics into Fibrin Loci in vivo. II Comparison of 9 Antibiotics: Effect of Dose and Degree of Protein Binding”
87. Binding of Antibiotics to Tissue Homogenate
88. Binding of Some Biogenic Amines in Tissues
89. Certain Aspects of Drug Binding to Non-Plasma Proteins as Illustrated by Studies with Cyclizine. Chlorcyclizine and Polymyxin B”
90. A New Generalized Non-Linear Pharmacokinetic Model and Its Implications
91. Pharmacokinetics of Highly Ionized Drugs III: Methylene Blue-Blood Levels in the Dog and Tissue Levels in the Rat Following Intravenous Administration
92. Protein Binding and the Excretion of Some Azo Dyes in Rat Bile
93. Absorption and Excretion of Riboflavin in the Rat: An Unusual Example of Non-Linear Pharmacokinetics”
94. Altered Bioavailability of Drugs in the Eye Due to Drug-Protein Interaction.
95. Binding of Basic and Acidic Drugs to Rat Tissue Subcellular Fractions
96. Methotrexate Pharmacokinetics”
97. The Disposition of Propranolol IV, A Dominant Role for Tissue Uptake in the Dose-Dependent Extraction of Propranolol by the Perfused Rat Liver”
98. Diphenylhydantoin: Absorption, Distribution, and Excretion
99. Serum Protein Binding of Thyroxine and Diphenylhydantoin
100. Plasma Protein Binding of Diphenylhydantoin in Patients with Epilepsy. Agreement Between the Unbound Fraction in Plasma and the Concentration in the Cerebrospinal Fluid
101. Effect of Protein Binding on the Distribution of 5,5-Diphenylhydantoin between Plasma and Red Cells
102. Plasma Levels of Anticonvulsants
103. Diphenylhydantoin as an Anticonvulsant: Protein Binding and Fluctuation of the Serum and CSF Levels in 40 Mentally Subnormal Epileptics
104. Serum Concentrations of Free Diphenylhydantoin and Their Relationship to Clinical Intoxication
105. Protein Binding of Diphenylhydantoin and Desmethylimipramine in Plasma from Patients with Poor Renal Function
106. The Alteration of Plasma Proteins in Uremia as Reflected in Their Ability to Bind Digitoxin and Diphenylhydantoin
107. Influence of Disease on Binding of Drugs to Plasma Proteins
108. Protein Binding of Drugs in Plasma from Patients with Acute Renal Failure
109. Plasma Protein Binding of Diphenylhydantoin in Normal and Hyperbilirubinemic Infants
110. A Comparison of the Binding of Drugs to Adult and Cord Plasma.
111. Plasma Protein Binding of Diphenylhydantoin in Man. Interaction with Other Drugs and the Effect of Temperature and Plasma Dilution
112. Diphenylhydantoin Metabolism in Uremia
113. Diphenylhydantoin Side Effects and Serum Albumin Levels
114. Plasma Protein Binding, Plasma Concentrations, and Effects of Diphenylhydantoin in Man
115. The Disposition of Propranolol 111 Decreased Half-life and Volume of Distribution as a Result of Plasma Binding in Man, Monkey, Dog and Rat”
116. Disposition of Propranolol VI, Independent Variation in Steady State Circulating Drug Concentration and Half-Life as a Result of Plasma Drug Binding in Man”
117. Interaction of Adrenal and Gonadal Steroids with Proteins in Human Plasma
118. The Miscible Pool and Turnover Rate of Hydrocortisone in Man
119. The Physiological Disposition and Metabolic Fate of Hydrocortisone in Man
120. Increased Exposure of Tissue to Cortisol in Late Pregnancy
121. Dynamics of Synthetic Corticosteroids in Man
122. The Binding of Steroids to Plasma Proteins in Normal Women and Women with Breast Cancer
123. Prednisone Side Effects and Serum Protein Levels
124. In vivo Studies of Steroid Dynamics in Man
125. Adrenal Glucocorticoid Control System
126. The Rate Constants for the Interaction of Cortisol and Trans-cortin and the Rate of Dissociation of Transcortin-Bound Cortisol in the Liver
127. Effect of Plasma Protein Binding on Elimination of Warfarin
128. Relationship between Plasma Protein Binding, Distribution, and Anticoagulant Action of Dicumarol
129. Relationship between Distribution, Elimination, and Anticoagulant Action of Dicumarol
130. Warfarin Resistance
131. Computation of Unbound Anticoagulant Values in Plasma.
132. Comparative Pharmacokinetics of Coumarin Anticoagulants VI: Effect of Plasma Protein Binding on the Distribution and Elimination of Bishydroxycoumarin by Rats
133. Comparative Pharmacokinetics of Coumarin Anticoagulants III. Factors Affecting the Distribution and Elimination of Bishydroxycoumarin in Isolated Perfusion Studies”
134. The Relationship of Pharmacokinetic Properties of Some Sulfonamides to Certain Physicochemical Parameters”
135. Correlation of in vivo Metabolism Rate and Physical Properties of Sulfonamides”
136. Integral Coefficients of Multi-Compartmental Pharmacokinetic Models
137. pH-Partition Behavior of Tetracycline
138. The Excretion and Distribution in Body Fluids of Tetracycline after I. V. Administration to Dog
139. Comparative Serum Binding, Distribution, and Excretion of Tetracycline and a New Analogue, Methacycline
140. Comparison of in vitro Activity and Clinical Pharmacology of Doxycycline with Other Tetracyclines
141. Distribution and Excretion of 4 Tetracycline Analogues in Normal Young Men
142. Absorption and Excretion of 5 Tetracycline Analogues in Normal Young Men”
143. Biological Half-Lives and Their Clinical Applications
144. Comparison of the Blood Levels Obtained After Single and Multiple Doses of Erythromycin Estolate and Erythromycin Sterate”
145. Serum Protein Binding of Erythromycin and Erythromycin-2-Propionate Ester”
146. Non-Linear Plasma Levels Response to High Doses of Naproxen”
147. Plasma Binding of Imipramine and Clinical Outcome”
148. Diphenylhydantoin Side Effects and Serum Albumin Levels”
149. Sensitivity to Tubocurarine and Alcuronium with Special Reference to Plasma Protein Patterns
150. Some Clinical Evidence for a Quantitative Relationship between Dose of Relaxant and Plasma Protein”
151. Clinical Significance of Thiopentone Binding to Haemoglobin and Plasma Proteins
152. Reciprocal Relation between Plasma Albumin Level and Hepatic Sulfobromophthalin Removal
153. False-Negative Bromsulfalein Test”
154. Abnormal Binding of Indocyanine Green with Serum Proteins in a Patient with Delayed ICG Clearance”
155. Interpretation of Serum CA++ in Patients with Abnormal Serum Proteins”
156. Variation in Plasma Calcium with Induced Changes in Plasma Specific Gravity, Total Protein and Albumin
157. On the Cause and Degree of Intraindividual Serum CA++ Variability
158. Drug Binding by Serum Albumin: Implication of Some Recent Observations”
159. Binding of Bromosulphthalein by Serum Albumin from Pregnant Women, Neonates, and Subjects on Oral Contraceptives”
160. Binding of Salicylic Acid and Sulphanilamide in Serum from Pregnant Patients, Cord Blood, and Subjects Taking Oral Contraceptives”
161. Interpretation of Drug Binding Changes in Relation to Protein Concentration”
162. Influence of Disease on Binding of Drugs to Plasma Proteins
163. Protein Binding of Drugs in Plasma from Patients with Acute Rend Failure
164. Decreased Drug Binding by Serum Albumin During Renal Failure
165. Abnormal Pharmacokinetics of Phenytion in a Patient with Uremia”
166. Protein Binding of Diphenylhydantoin and Dismethyl-imipramine in Plasma from Patients with Poor Renal Function
167. The Alteration of Plasma Proteins in Uremia as Reflected in Their Ability to Bind Digitoxin and DPH
168. Diphenylhydantoin Metabolism in Uremia”
169. Complication During Clofibrate Treatment of Nephrotic-Syndrome Hyperlipoproteinemia
170. Lipid Metabolism in Acute and Chronic Renal Failure”
171. Effects of FFA on Binding of Drugs by Bovine Serum Albumin, by Human Serum Albumin, and by Rabbit Serum”
172. The Effects of Hemodialysis on the Binding Capacity of Albumin
173. Age Differences in Drug Binding by Plasma Proteins: Studies on Human Foetuses, Neonates, and Adults
174. A Comparison of the Binding of Drugs to Adult and Cord Plasma
175. The Binding of Bupivacaine to Material and Foetal Plasma Proteins
176. Binding of Anilide-Type Local Anesthetics in Human Plasma
177. The Binding of Sulfaphenazole to Fetal, Neonatal, and Adult Human Plasma Albumin
178. The Binding of Salicylate to Plasma Protein from Several Animal Species
179. The Binding of Salicylate to Plasma Proteins in Different Species”
180. The Binding of 3 Penicillins in the Plasma of Several Mammalian Species as Studied by Ultrafiltration at Body Temperature
181. The Relation between the Binding of Sulfonamides to Albumin and Their Antibacterial Efficacy
182. Binding Capability of Various Sulfonamides to Serum of Different Animal Species
183. Species Differences in the Binding of Phenylbutazone to Plasma Albumin
184. Binding of 5, 5-Diphenylhydantoin and Its Major Metabolites to Human and Rat Plasma Protein
185. Extent of Plasma Protein Binding of Amphetamine in Different Species”
186. Species Differences in the Plasma Protein Binding of Desipramine”
187. Relation between Binding of Plasma Proteins, Apparent Volume of Distribution and Rate Constant of Disposition and Elimination for Chlorpromazine in 3 Species”
188. Potentiation of Anticoagulant Effect of Warfarin by Phenylbutazone
189. Potentiation of Warfarin Induced Hypothrombonemia by Chloral Hydrate”
190. Interaction between Chloral Hydrate and Warfarin
191. A Drug Induced Change in the Distribution and Renal Excretion of Sulfonamides
192. Influence of Binding on the Toxicity of Bilirubin
193. Sulphaphenazole Induced Hypoglycemic Attacks in Tolbutamide Treated Diabetics
194. Plasma Protein Binding of Methotrexate and Its Displacement by Various Drugs”
195. Plasma Protein Binding of Tricyclic Antidepressants in Man
196. The Roentgen Contrast Media Potentiation of Nembutal Anesthesic in Rats
197. The Displacement of L-Tryptophan and Dipeptides from Bovine Albumin in vitro and from Human Plasma in vivo by Antirheumatic Drugs
198. Total and Free Plasma Tryptophan Concentration in Rheumatoid Disease”
199. Action of Chlorthiazide on the Distribution, Excretion, and Hypotensive Effect of Pempidine in Man
200. Effect of Drugs on Urate Binding to Plasma Proteins”
201. Increasing Excretion of Urate with Displacing Agents in Man”
202. Biochemical Properties of Anti-Inflammatory Drugs, XI, Inhibition of Urate Binding to Human Albumin by Salicylate and Phenylbutazone Andggs and Some Novel Anti-Inflammatory Drugs
203. Specificity of Binding to Human Serum Albumin
204. Binding of Certain Non-Steroidal Anti-Inflammatory Agents and Uricosuric Agents to Human Serum Albumin”
205. Lidocaine Disposition Kinetics in Monkey and Man. I. Prediction by a Perfusion Model
206. The Binding Behavior of Phenothiazine and Structurally Related Compounds to Albumin from Several Species
207. Die Bindung von Steroid Hormonen und von Steroid Quanyl-Hydrazonen an Serum-Albumin
208. Binding of Dapsone (DDS) and Monacetyldapsone (MADDS) by Plasma of Animals and Man”
209. Plasma Protein Binding of Tricyclic Antidepressants in Man”
210. Correlation of Serum Binding of Penicillin with Partition Coefficient
211. The Role of Substituents in the Hydrophobic Binding of Phenols by Serum and Mitochondrial Proteins”
212. Analysis of the Structure Activity Relationship of the Sulfonamide Drugs Using Substituent Constant”
213. Hydrophobic Binding of Sulfonamide Drugs with Serum Albumin”
214. Effect of Physicochemical and Pharmacokinetic Properties of Barbiturates on the Induction of Drug Metabolism
215. Intermolecular Reactions Between Proteins and Organic Compounds
216. Passive Permeation of Organic Compounds Through Biological Tissue: A Non-Steady State Theory
217. Interaction of Plasma Proteins with Related 1,3-Propanediol Dicarbomates”
218. The Combination of Organic Anions with Serum Albumin VIII Fatty Acid Salts”
219. The Linear Free-Energy Relationship between Partition Coefficient and the Binding and Conformational Perturbation of Macromolecules by Small Organic Compounds”
220. Binding of Apolar Molecules by Serum Albumin”
221. The Role of Hydrophobic Bonding in the Binding of Organic Compounds by Bovine Hemoglobin”
222. Physicochemical Studies of Analgesics: The Protein Binding of Some p-Substituted Acetanilides
223. A New Buccal Absorption Model
224. A Method for the Correlation of Biological Activity and Chemical Structure”
225. Determination of Binding Constants of Serum Albumin for Penicillin”
226. Interpretation of Protein-Drug Interaction through Fraction Bound and Relative Contribution of Secondary Sites
227. Microultrafitration Technique for Drug-Protein Binding Determination in Plasma
228. Binding of Dapsone and Monoacetyl Dapsone by Human Plasma Protein”
229. Plasma Binding of Betamethasone- 3H, Dexamethasone-3H, and Cortisol-14C: A Comparative Study
230. Metabolic Studies of Allopurinol an Inhibitor of Xanthine Oxidase”
231. Binding of d-Tubocurarine to Plasma Proteins in Normal Man and in Patients with Hepatic or Renal Disease”
232. Disposition of Glutethimide in Man
233. Plasme Protein Binding of Chlorpromazine
234. Binding of dl-Tetrahydrocannabinol to Human Plasma Proteins
235. Binding of Diazoxide and Other Benzothiadimines to Human Albumin
236. Plasma Protein Binding of Amphetamine, Catecholamines and Related Compounds
237. Methadone Binding to Human Plasma Albumin
238. Binding of Prostaglandins to Human Serum Albumin”
239. The Binding of Steroids to Plasma Proteins in Normal Women and Women with Breast Cancer
240. Serum Protein Binding of the Aminoglycoside Antibiotics.
241. Binding of Phenothiazines to Bovine Serum Albumin and Related Phenomena
242. Trimethaprin-Sulfamethoxazole: Pharmacodynamic Effects of Urinary pH and Impaired Renal Function-Studies in Humans
243. Complex Formation between Macromolecules and Drugs, Part VII, The Binding of Some Barbiturates to Human Serum Albumin at Varying pH
244. Protein Binding, VI, Binding of Phenols to Bovine Serum Albumin
245. Clinical Pharmacologic Observations on 6-Mercaptopurine and 6-Methylthiopurine Ribonucleoside
246. Flucloxacillin: New Semi-synthetic Isoxazolyl Penicillin
247. Protein Binding, II, Binding of Aromatic Carboxcyclic Acids to BSA”
248. Protein Binding, III, Binding of Sulfonamides to Bovine Serum Albumin”
249. Binding of Sodium Taurocholate by Bovine Serum Albumin”
250. Binding of 5, 5-Diphenylhydantoin and Its Major Metabolites to Human and Rat Plasma Protein”
251. Binding of Catecholamines to Human Serum Albumin”
252. Prostaglandin Binding in Human Serum Following the Polarity Rule”
253. Interaction of Prostaglandins with Blood Plasma Protein”
254. Interaction of the Anticoagulant Drug Warfarin and Its Metabolites with Human Plasma Albumin
255. Physiological Disposition of Fenoprofen in Man, 3, Metabolism and Protein Binding of Fenoprofen
256. Effect of Protein Binding on Levels of Ampicillin and Cloxacillin in Synovial Fluid”
257. Binding of Anilide-Type Local Anesthetics in Human Plasma”
258. Plasma Protein Binding of Tricyclic Antidepressant Drugs”
259. Influence of Protein Binding on the Excretion of Some Sulfanilamidopyrimidines in Man
260. The Binding of Chlorpromazine to Human Serum Albumin”
261. Complex Formation between Macromolecules and Drugs, V, A Study of Human Serum Albumin (HSA) Binding of Some 4-Sulfanilamidopyrimidines and 2Sulfanilamidopyrimidines”
262. Complex Formation between Macro-molecules and Drugs, IV, Binding of Sulfa Drugs to Human Serum Albumin at Varying pH Values
263. Extent of Plasma Binding of Amphetamines in Different Species”
264. Binding of Estrone Sulfate in Human Plasma
265. A Study of the Interaction of Tetracycline with Human Serum Lipo-protein and Albumin
266. A Theoretical Study of Multiple Drug-Protein Binding Data Exemplified by the Dicumarol Serum Albumin Interaction”
267. Interaction of Albumin and Fusidic Acid
268. Protein Binding of Small Molecules I, Effect of pH and Inorganic Salts on the Combination of Phenol Red with Protein”
269. Furosemide Concentration in Serum and Urine and Its Binding by Serum Protein as Measured Fluoro-metrically”
270. Protein Binding and Lipophilic Nature of Ataractics of the Meprobamate and Diazepine Group.”
271. The Displacement of Phenylbutazone 14C and Warfarin 14C from Human Albumin by Various Drugs and Fatty Acids
272. Studies on Therapy of Staphylococcal Infection in Monkeys, V, Comparison of Cephalexin, Oxacillin, Cloxacillin, Decloxacillin, and Nafcillin
273. Displacement of Warfarin from Human Albumin by Diazoxide and Ethacrynic, Mefenamic, and Nalidixic Acids”
274. Binding of Ethacrynic Acid to Bovine Serum Albumin
275. In vitro Studies of TC-99-M-Pertechnetate Binding by Human Serum and Tissue
276. Importance of Tissue and Plasma Binding in Determining the Retention of Norchlorcyclizine and Norcyclizine in Man, Dog, Rat
277. Species Differences in the Albumin Binding of 2,4,6-Trinitrobenzaldehyde, Chlorophenoxyacitate Acids, 2-(4′-Hydroxybenzeneazo) Benzoic Acid and Some Other Acidic Drugs–The Unique Behavior of Rat Plasma Albumin
278. The Relationship between the Binding of Thiophental to Plasma and Its Distribution into Adipose Tissue in Man”
279. Studies on Plasma Protein Binding of Carbamazepine
280. Studies with Some Novel Uricosuric Agents and Their Metabolites
281. Interindividual Differences in Plasma Protein Binding of Nortriptyline in Man–A Twin Study”
282. Plasma Protein Binding of Diphenylhydantoin in Patients with Epilepsy”
283. Serum Concentrations of Free Diphenylhydantoin and Their Relationship to Clinical Intoxication”
284. Interaction of Vinblastine, Vincristine, and Colchicine with Serum Proteins
285. Binding of Sulfonylureas to Serum Proteins
286. Plasma Protein Binding of Riboflavin and Riboflavin 5′-Phosphate in Man”
287. Tetracycline Binding to Bovine Serum Albumin Studied by Fluorescent Technique”
288. Plasma Protein Binding of Antineoplastic Drugs in Rats and Humans”
289. Interaction of Bishydroxycoumarin with Human Serum Albumin
290. Studies on Protein Binding, I, Interaction of pHydroxybenzoic Acid Esters with Bovine Serum Albumin
291. Binding of Cortisol and Its Degradation Products by Human Serum Albumin”
292. Serum Protein Binding of Erythromycin, Lincomycin, and Clindamycin”
293. Binding of Sulfonylureas to Serum Albumin”
294. In vitro Binding of Pentylenetetrazol to Plasma Protein”
295. Hydrophobic and Ionic Interaction of Phenothiazine Derivatives with Bovine Serum Albumin”
296. Optical Studies of Drug Protein Complexes, II, Interaction of Phenylbutazone and Its Analogues to Human Serum Albumin”
297. Metabolite of Probenecid: Chemical, Physical, and Pharmacological Studies”
298. Studies with Thiohexital an Anesthetic Barbiturate Metabolized with Unusual Rapidity in Man”
299. Binding of Digitoxin and Some Related Cardenolides to Human Plasma Protein
300. Equilibrium Dialysis Study of the Binding of Chlorpromazine to Serum Proteins
301. Some Physicochemical Factors Influencing the Binding of Sulfonamides to Human Albumin in vitro”
302. Interaction of Sulfonylureas with Plasma Proteins”
303. Biological Significance of Serum Albumin Binding Parameters Determined in vitro from Clofibrate Related Hypolipemic Drugs: Use of 2-(4′-Hydroxybenzenao) Benzoic Acid to Mirror L-Tyrosine Binding to and Displacement from Serum Albumin”
304. Measurement of Drug Displacement by Continuous Ultrafiltration”
305. Structure Relationship for Binding of Sulfonamides and Penicillins to Bovine Serum Albumin by Fluorescence Probe Technique”
306. Interaction of Drugs with Proteins, I, Binding of Tricyclic Thymoleptics to Human and Bovine Plasma Protein”
307. Interaction of Drugs with Proteins, II, Experimental Methods, Treatment of Experimental Data, and Thermodynamics of Binding Reactions of the Thymoleptic Drugs and Model Dyes”
308. Binding of Salicylate to Crystalline Bovine Serum Albumin and to Fraction V Bovine Serum Albumin”
309. Dynamic Dialysis as a Method for Studying Protein Binding, II, Evaluation of the Method with a Number of Binding Systems.”
310. Binding of BSP by Serum Albumin from Pregnant Women, Neonates, and Subjects on Oral Contraceptives”
311. Binding of Salicylic Acid and Sulphanilamide in Serum from Pregnant Patients, Cord Blood, and Subjects Taking Oral Contraceptives”
312. Effect of Temperature on the Binding of Salicylate by Human Serum Albumin
313. Salicylate Interaction with Penicillin and Secobarbital Binding Sits on Human Serum Albumin.”
314. Methadone Binding to Human Plasma Proteins”
315. Effects of Protein Binding on Levels of Ampicillin and Cloxacillin in Synovial Fluid
316. Reversibility of Protein Binding of Penicillin: An in vitro Study Employing a Rapid Diafiltration Process
317. Plasma Protein Binding of Diphenylhydantoin in Normal and Hyperbilirubinemic Infants
318. Non-linear Plasma Level Response to High Doses of Naproxen”
319. PIasma Protein Binding of Diphenylhydantoin, Effect of Sex Hormone, Renal and Hepatic Disease”
320. Effect of Halofenate on Binding of Various Drugs to Human Plasma Proteins and on the Plasma Half-Life of Antipyrine in Monkey”
321. Phenylbutazone-Sodium Warfarin Binding Using a Fluorescent Probe Technique”
322. Dialysis and Circular Dichroism Study of the Binding of Sulfaethidole to Crystalline and Fraction V BSA”
323. Flucloxacillin, a New Isoxazolyl Penicillin, Compared with Oxacillin, Cloxacillin, and Dicloxacillin
324. Kinetics of Diphenylhydantoin in Uremia Patients, Consequence of Decreased Plasma Protein Binding
325. The Distribution Pattern of a Series of Tricyclic and Bicyclic Thymoleptics Compared with Their Lipophilic Properties and Binding to Plasma Protein
326. Dopamine: Renal Tubular Transport in the Dog and Plasma Binding Studies”
327. γ-Globulin Binding of Morphine in Heroin Addicts”
328. Binding of Digoxin to Human Serum Proteins: Influence of pH on the Binding of Digoxin to Human Albumin
329. Temperature Dependence of Salicylic Acid Binding to Albumin as Studied by Frontal Gel Chromotography”
330. The Binding of Amphetamine and Related Compounds to Plasma Proteins”
331. Species Differences in Plasma Binding of Morphine and Codeine
332. Tritiated Digoxin, XV, Serum Protein Binding in Human Subjects
333. Protein Binding of Three Tritiated Muscle Relaxants
334. The Binding of Aliphatic Carbamates to Bovine Serum Albumin
335. Binding of Catecholamines to Human Serum Albumin”
336. The Measurement of Binding Constants Using Circular Dichroism Binding of Phenylbutazone and Oxyphenylbutazone
337. The Binding of Indomethacin, Salicylic Acid, and Phenobarbitone to Human Whole Blood in vitro
338. Preparative Ultracentrifugation of Small Samples of Plasma and the Protein Binding of Methaqualone”
339. Studies on the Relationship of Protein Binding and Gel-Affinity of Antibiotics Including Penicillins”
340. Comparative Study of the Binding of Coumarin Anticoagulants and Serum Albumin
341. Binding of Catechol Derivatives to Human Serum Proteins”
342. Characterization of the Binding of Benzodiazepines to Human Serum Albumin
343. Protein Binding, Renal Clearance and Volume of Distribution of Kanamycin”
344. Protein Binding of Different Cardiac Glycosides, Determined by Means of the Sephadex Gel Filtration Method”
345. Albumin Binding and Hydrophobic Character of Promazine and Chlorpromazine Metabolities
346. The Effect of Some Drugs on the Protein Binding of Phenol Red and Digitoxin
347. The Interaction of Phenothiazine Derivatives with Bovin Serum Albumin
348. On the Characteristics of the Binding of Cardiac Glycosides by Plasma Proteins
349. The Significance of the Benzene Rings in Protein Binding of Promazine and Chlorpromazine
350. The Protein Binding of Some Psychoactive Drugs with a Tricyclic Ring System in Relation to Their Chemical Constituents
351. Differentiation between Drug-Binding Plasma Proteins”
352. Quantitative and Qualitative Aspects of the Plasma Protein Binding of Carbenoxrolone, an Ulcer-Healing Drug”
353. The Binding Capacity of Albumin and Renal Disease
354. Furosemide Binding to Human Albumin and Plasma of Nephrotic Children
355. Morphine Binding to Human Plasma Protein
356. The Binding of Catecholamines to Human Serum Protein
357. Meperidine Kinetics in Man: Intravenous Injection in Surgical Patients and Volunteers
358. Cortisol Binding to Protein in Plasma in the Human Neonate and Infant
359. Binding of Rifampicin by Human Plasma Protein
360. Protein Binding of Rifampicin: A Review
361. Protein Binding of Rifampicin to Different Individual Sera
362. A New Single Approach to Study the Protein Binding of Volatile and Gaseous Compounds. I. Propellants, Halothane and Cyclopropane
363. Comparative Binding of Disopyramide Phosphate and Quinidine Sulfate to Human Plasma Protein
364. Binding of Adrenergic Beta-Receptor Antagonists to Human Serum Albumin
365. Binding of Two Adrenergic Beta-Receptor Antagonists, Alprenolol and H 93/96 to Human Serum Protein
366. Complex Formation between Macromolecules and Drugs X
367. The Influence of Age on the Activity of Acetylsalicylic Acid-Esterase and Protein-Salicylate Binding
368. Binding of C14-Furosemide to Human Albumin and Plasma of Nephrotic Children”
369. Hepatic Protein Binding of Folate
370. Binding of (+)- and (−).Δ′-Tetrahydrocannabinofs and (-)-7-hydroxy-Δ′-TetrahydrocannabinoI to Blood Cells and Plasma Proteins in Man
371. Studies on the Interaction of Δ9-Tetrahydrocannabinol with Plasma Lipoprotein
372. Plasma Protein Binding of 7-hydroxy-Δ′-Tetrahydrocannabinol: An Active Δ′ Tetrahydrocannabinol Metabolite
373. Binding of Δ′-Tetrahydrocannabinol to Human Plasma Protein
374. Microultrafiltration Technique for Drug-Protein Binding Determination in Plasma
375. The Binding of Paracetamol to Plasma Proteins of Man and Pig
376. Effect of Fatty Acids on the Binding of Bilirubin to Albumin
377. Competitive Binding of Free Fatty Acids and Bilirubin to Albumin: Difference in HABA Dye Versus Sephadex G-25 Interpretation of Results
378. Effect of Free Fatty Acid Concentration on the Transport and Utilization of Other Albumin-Bound Compounds: Hydroxyphenylazobenzoic Acid
379. Serum Tryptophan Level after Carbohydrate Ingestion: Selective Decline in Non-Albumin Bound Tryptophan Concentration with Reduction in Serum Free Fatty Acid
380. Diphenylhydantoin Binding to Roteins in Plasma and Its Dependence on Free Fatty Acids and Bilirubin Concentration in Dog and Newborn Infants.
381. Relationship between Lipolysis and Storage of Phenobarbital in Adipose Tissue
382. Relationship between Lipolysis and Storage of Diphenylhydantoin in Adipose Tissue
383. Effect of in vivo Elevation of Free Fatty Acids on Rotein Binding of Drugs
384. Species Difference in the Albumin Binding of 2,4,6-Trinitrobezaldehyde, Chlorophenoxyacetic Acid, 2-(4′-hydroxyben-zeneazo) Benzoic Acid and Some Other Acid Drugs–-The Unique Behavior of Rat Plasma Albumin
385. Spontaneous and Induced Alteration in the Anion Binding Properties of Human Albumin”
386. Role of Serum Albumin in the Transport and Storage of Dehydro-epiandrosterone Sulfate
387. Amino Acid Composition of Serum Albumin in Normal Individuals and in Patients with Neumatoid Arthritis
388. Inter and Intra Species Differences in the Binding Anionic Compounds to Albumin
389. The Significances of Protein Binding of Contrast Media in Roentgen Diagnosis
390. Optical Studies of Drug-Protein Complexes V,” The Interaction of Phenylbutazone, Flufenamic Acid and Dicoumarol with Acetylsalicylic Acid-Treated Serum Albumin
391. Acetylation of Human Serum Albumin by Acetylsalicylic Acid
392. Structural Changes in Human Serum Albumin Induced by Ingestion of Acetylsalicylic Acid”
393. Spectroscopic Techniques in the Study of Protein Binding: The Use of 1-Anilino-8-naphthalenesulphonate as a Fluorescent Probe for the Study of the Binding of Iophenoxic and Iopanoic Acids to Human Serum Albumin
394. Structural Effects of Anionic Azo Dyes on Serum Albumin
395. Macromolecular-Small Molecule Interaction. Strong Binding and Cooperativity in a Model Synthetic Polymer
396. Effect of Nonsteroidal Anti-inflammatory Drugs on Plasma Protein-Thyroxine Interaction
397. The Disposition of Dapsone and Monoacetyldapsone in the Dog
398. Characteristics of the Binding of Dapsone and Monoacetyldapsone by Serum Albumin
399. Effect of Bilirubin on the Distribution, Elimination and Anticoagulant Action of Dicumarol in Gunn Rats
400. Potentiation of Anticoagulant Effect of Warfarin by Phenylbutazone
401. Combined Effect of Sodium Warfarin and Phenylbutazone
402. Phenylbutazone Potentiation of Anticoagulant Effect: Fluorometric Assay of Warfarin
403. The Effect of Various Drugs on the Binding of Warfarin-C14 to Human Albumin
404. The Displacement of Phenyl-butazone-C14 and Warfarin from Human Albumin by Various Drugs and Fatty Acids
405. Effect of Phenylbutazone OR the Distribution, Elimination and Anticoagulant Action of Dicumarol in Rats
406. Critical Evaluation of Use of Effective Protein Fractions in Developing Pharmacokinetic Models for Drug Distribution
407. Elimination of Chloramphenicol and Thiamphenicol in Subjects with Cirrhosis of the Liver
408. Phenylbutazone and Isoniazed Metabolism in Patients with Liver Disease in Relation to Previous Drug Therapy
409. Interaction of Serum Albumin and Bilirubin at Low Concentration
410. Sephadex Adsorption of Bilirubin from Neonatal and Adult Serum”
411. The Binding of Unconjugated Bilirubin by Human Sera and Purified Albumin
412. Pharmacokinetic Implications of Bilirubin Displacement
413. Two Hepatic Cytoplasmic Protein Fractions, Y and Z, and Their Possible Role in the Hepatic Uptake of Bilirubin, Sulfobromophthalein and other Anions”
414. Bilirubin Binding to Hepatic Y and 2 Protein (Ligandin): Tissue Bilirubin Concentration in Phenobarbital Treated Gunn Rat
415. Influence of Albumin on the Hepatic Uptake of Unconjugated Bilirubin
416. Influence of Albumin on the Extravascular Distribution of Unconjugated Bilirubin
417. Studies of Y and Z, Two Hepatic Cytoplasmic Organic Anion-Binding Proteins: Effect of Drugs, Chemicals, Hormones and Cholestasis
418. Enhancement of Glucuronide Conjugation Capacity in a Hyperbilirubinemic Infant Due to Apparent Enzyme Induction by Phenobarbital
419. A Difference in Mortality Rate and Incidence of Kericterus among Premature Infants Allotted to Two Prophylactic Antibacterial Regimens
420. Influence of Binding on the Toxicity of Bilirubin
421. γ-Globulin Binding of Morphine in Heroin Addicts
422. Reversal of the Pharmacological and Toxic Effects of Cardiac Glycosides by Specific Antibodies
423. Immunological Protection Against Digoxin Toxicity
424. Reversal of Digoxin Toxicity with Specific Antibodies
425. The Effect of Digoxin-Specific Antibodies on the Distribution of Digoxin-3 H in Dog
426. Binding of Certain Acidic Drugs to Human Albumin: Theoretical and Practical Estimation of Fundamental Parameters